131 related articles for article (PubMed ID: 34089074)
1. MRI-Derived Sarcopenia Associated with Increased Mortality Following Yttrium-90 Radioembolization of Hepatocellular Carcinoma.
Guichet PL; Taslakian B; Zhan C; Aaltonen E; Farquharson S; Hickey R; Horn CJ; Gross JS
Cardiovasc Intervent Radiol; 2021 Oct; 44(10):1561-1569. PubMed ID: 34089074
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area.
Faron A; Sprinkart AM; Pieper CC; Kuetting DLR; Fimmers R; Block W; Meyer C; Thomas D; Attenberger U; Luetkens JA
Eur J Radiol; 2020 Apr; 125():108889. PubMed ID: 32087468
[TBL] [Abstract][Full Text] [Related]
3. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases.
Faron A; Pieper CC; Schmeel FC; Sprinkart AM; Kuetting DLR; Fimmers R; Trebicka J; Schild HH; Meyer C; Thomas D; Luetkens JA
Eur Radiol; 2019 Sep; 29(9):4709-4717. PubMed ID: 30689036
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
[TBL] [Abstract][Full Text] [Related]
6. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
8. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
9.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
12. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
[TBL] [Abstract][Full Text] [Related]
13. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
[TBL] [Abstract][Full Text] [Related]
14. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
[TBL] [Abstract][Full Text] [Related]
15.
Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
[TBL] [Abstract][Full Text] [Related]
16. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ
Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711
[TBL] [Abstract][Full Text] [Related]
17. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
[TBL] [Abstract][Full Text] [Related]
18. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
[TBL] [Abstract][Full Text] [Related]
19. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.
Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H
J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
